Nachrichten zur Nektar Therapeutics Corp. Aktie

Nektar Therapeutics chief R&D officer sells $48,048 in stock By Investing.com

Nektar Therapeutics chief R&D officer sells $48,048 in stock…

Multiple Catalysts Ahead For Nektar Therapeutics

…

Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Transcript

…

Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of -19.05% and 36.26%, respectively, for the quarter ended June 2024. Do the…

Nektar Therapeutics Likely To Drift And Wobble Ahead Of Key Phase II Data In 2025

…

Nektar Therapeutics executive sells over $12k in shares By Investing.com

Nektar Therapeutics executive sells over $12k in shares…

Nektar Therapeutics, Inc. (NKTR) Q1 2024 Earnings Call Transcript

…

Earnings call: Nektar Therapeutics unveils drug development progress By Investing.com

Earnings call: Nektar Therapeutics unveils drug development progress…

Nektar Therapeutics (NKTR) Q4 2023 Earnings Call Transcript

…

Nektar Therapeutics secures $30 million in private financing By Investing.com

Nektar Therapeutics secures $30 million in private financing…

Nektar Therapeutics Q4 2023 Earnings Preview

…

Nektar Therapeutics (NKTR) Q3 2023 Earnings Call Transcript

…

Nektar Therapeutics (NKTR) Incurs Wider-Than-Expected Q3 Loss

Nektar (NKTR) misses third-quarter estimates for the bottom line but beats the same for the top line.…

5 Top-Ranked Stocks With Rising P/E for Solid Returns

Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include Nektar Therapeutics (NKTR), Energous…

Insiderhandel: President & CEO verkauft Aktien von Nektar Therapeutics im Wert von 15.598$

Robin, Howard W. - Vorstand - Tag der Transaktion: 2023-08-16...…

Insiderhandel: Chief R&D Officer verkauft Aktien von Nektar Therapeutics im Wert von 7.568$

Zalevsky, Jonathan - Vorstand - Tag der Transaktion: 2023-08-16...…

Insiderhandel: Chief Legal Officer verkauft Aktien von Nektar Therapeutics im Wert von 5.632$

Wilson, Mark Andrew - Vorstand - Tag der Transaktion: 2023-08-16...…

Nektar Therapeutics (NKTR) Reports Q2 Loss, Lags Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of 10% and 2.13%, respectively, for the quarter ended June 2023. Do the…

Nektar Therapeutics Q2 Loss decreases, beats estimates

WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR) revealed Loss for second quarter that decreased from last year and beat the Street…

Nektar reportedly sues Lilly for bungling clinical data on dermo drug

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Why Is Nektar Therapeutics Stock Surging Today?

Nektar Therapeutics Inc (NASDAQ: NKTR) said its former partner Eli Lilly And Co (NYSE: LLY) had presented "erroneous data" from two Phase 1b…

Nektar stock soars on new data for rezpeg after Eli Lilly got it wrong

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Nektar Therapeutics sues Eli Lilly over autoimmune disease treatment

...Aug 7 (Reuters) - Nektar Therapeutics on Monday sued Eli Lilly......…

UPDATE 1-Nektar Therapeutics sues Eli Lilly over autoimmune disease treatment

...(Adds shares in paragraph 6, background throughout) Aug 7 (Reuters... not immediately respond to Reuters request for comment. Nektar......…

Nektar rallies on releasing new data for rezpeg after Eli Lilly got it wrong

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Nektar Therapeutics’ stock jumps premarket after it says data presented by Eli Lilly for a skin treatment was incorrectly calculated

Nektar Therapeutics’ stock NKTR jumped 12.7% in premarket trade Monday, after the company said that efficacy data previously generated…

Form 8-K NEKTAR THERAPEUTICS For: Aug 07

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Nektar Therapeutics’ stock up 5% premarket

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets

SAN FRANCISCO, Aug. 1, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter…

Sequans Communications: Sequans Monarch 2 GM02S NEKTAR EVKs Now Available on Verizon ThingSpace Marketplace

Paris, France--(Newsfile Corp. - July 5, 2023) - Now Available for purchase on Verizons ThingSpace Marketplace are evaluation kits for…

Insiderhandel: Aufsichtsrat verkauft Aktien von Nektar Therapeutics im Wert von 17.100$

Whitfield, Roy A. - Aufsichtsrat - Tag der Transaktion: 2023-06-14...…

Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference

SAN FRANCISCO, June 12, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) senior management is scheduled to participate in a virtual…

Form 8-K NEKTAR THERAPEUTICS For: Jun 08

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Insiderhandel: President & CEO verkauft Aktien von Nektar Therapeutics im Wert von 14.660$

Robin, Howard W. - Vorstand - Tag der Transaktion: 2023-05-16...…

Insiderhandel: Chief R&D Officer verkauft Aktien von Nektar Therapeutics im Wert von 7.050$

Zalevsky, Jonathan - Vorstand - Tag der Transaktion: 2023-05-16...…

Insiderhandel: Chief Legal Officer verkauft Aktien von Nektar Therapeutics im Wert von 5.431$

Wilson, Mark Andrew - Vorstand - Tag der Transaktion: 2023-05-16...…

Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of 3.85% and 4.83%, respectively, for the quarter ended March 2023. Do the…

Nektar Therapeutics Q1 Loss increases, misses estimates

WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR) released Loss for its first quarter that increased from the same period last year…

Nektar Regains Full Rights Of REZPEG From Eli Lilly, Plans To Initiate Phase 2b Study

WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR) Thursday announced that it will be regaining the full rights to REZPEG from Eli…

Nektar (NKTR) Starts New Restructuring Plan to Curb Cash Burn

The new restructuring plan will allow Nektar (NKTR) to extend its cash runway into mid-2026. The company plans to reduce…

Nektar Chief Medical Officer Brian Kotzin, CFO Jillian Thomsen to step down

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Nektar Therapeutics up 7% after hours on restructuring plan

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Nektar Cuts 60% of San Francisco Workforce, Names New Execs in Turnaround Plan

Nektar Cuts 60% of San Francisco Workforce, Names New Execs in Turnaround Plan...…

Form 8-K NEKTAR THERAPEUTICS For: Apr 17

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K NEKTAR THERAPEUTICS For: Apr 06

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics

Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics are part of the Zacks Industry Outlook article....…

dpa-AFX ProFeed